Last reviewed · How we verify
Mepact (MIFAMURTIDE)
At a glance
| Generic name | MIFAMURTIDE |
|---|---|
| Sponsor | Takeda France SAS |
| Drug class | mifamurtide |
| Target | Nucleotide-binding oligomerization domain-containing protein 2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2009 |
Approved indications
- Osteosarcoma of bone
Common side effects
Key clinical trials
- Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma
- Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (PHASE2)
- Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study
- ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma (PHASE2)
- ABCB1/P-glycoprotein Expression Influence on Non-metastatic Osteosarcoma of the Extremities
- A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS) (PHASE2)
- Surveillance Study of Patients With Newly Diagnosed Osteosarcoma
- Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |